

Sinovac announces annual capacity of 2 B doses of COVID-19 vaccine

02 April 2021 | News

It is estimated that over 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries



Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production.

Including this new production line, Sinovac's annual capacity of CoronaVac® has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China.

It is estimated that over 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries. The safety and effectiveness of CoronaVac® has been proven gradually along with the rollout of the vaccination around the world.

Sinovac will continue to promote the production, supply, and various research studies of CoronaVac®, in order to ensure quality and safety, strive to meet the pandemic prevention and control needs, and make positive contributions to the availability and affordability of the COVID-19 vaccine on a global basis.